PHRRFPharmaTher Holdings Ltd.

About PharmaTher Holdings Ltd. (PHRRF)

PharmaTher Holdings Ltd. (PHRRF) is a Biotechnology company headquartered in Toronto, ON, Canada whose shares trade over-the-counter on the OTCQB tier.

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is focused on the development and commercialization of Ketamine to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. PharmaTher owns 49% of Sairiyo Therapeutics Inc., which focuses on advancing the clinical development of an improved and patented enteric-coated orally bioavailable formulation of cepharanthine (PD-001) to treat responsive cancers and infectious diseases, including COVID-19.

Products and services

PharmaTher develops and commercializes specialty pharmaceuticals exhibiting growing adoption and permitting novel delivery methods to enhance patient outcomes and prescriber workflow. The Company’s lead product is Ketamine to fill the unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications.

PHRRF key facts

Ticker symbol

PHRRF

Market tier

OTCQB

Sector

Healthcare

Industry

Biotechnology

Headquarters

Toronto, ON, Canada

Country of incorporation

CA

Year of incorporation

2020

Employees

2

Estimated market cap

$11.95M (as of Apr 9, 2025)

Shares outstanding

88,519,065

Reporting standard

International Reporting: Canadian Securities Exchange

Audit status

Audited

Fiscal year end

5/31

Latest filing

Interim Financial Report (Nov 30, 2024)

PharmaTher Holdings Ltd. leadership

• Fabio Andrea Chianelli — CEO
• Carmelo Marrelli — CFO
• Andrew Charles Newbury — Corporate Secretary
• Hugh Ferreira — Consultant

Explore more: Biotechnology stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with P